Incannex Healthcare has developed plans for the commercialization of its psychedelic-assisted psychotherapy business. Incannex has been developing the commercialization plans for psychedelic clinics for some time, well before the TGA decision to down-schedule psilocybin for treatment-resistant depression and MDMA for Post-Traumatic Stress Disorder was announced, under the leadership of Peter Widdows, a long-standing Director of the Company. The Company has entered a partnership with Australia’s leading clinical psychedelic professionals, all of whom have extensive experience within clinical psychedelic research, treatment, and training. The Company is at an advanced stage of negotiations over premises in Melbourne, Australia, which has a population of 5.2M people. This first ‘model’ clinic is expected to open before the end of 2023. Once the operation of the model clinic is running smoothly, the Company will begin rapid expansion within Australia and overseas, where legislation allows.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IXHL:
- Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts
- Incannex announces results of interim review on Phase 2 program for GAD
- Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment
- Incannex engages Catalent to develop, manufacture cGMP-grade psilocybin drug
- Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use